ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1683

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Philip J Mease1, Chitra Karki2, Mei Liu2, Arthur Kavanaugh3, Renganayaki Pandurengan2, Christopher T. Ritchlin4, Jacqueline B. Palmer5 and Jeffrey D. Greenberg2,6, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of California San Diego, La Jolla, CA, 4Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6New York University School of Medicine, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, patient-reported outcome measures, Psoriatic arthritis, registry and spine involvement

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The objective of this analysis was to understand the prevalence and describe the baseline characteristics of PsA patients with and without axial involvement in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) registry.

Methods: This cross-sectional descriptive study included all patients with PsA enrolled in the Corrona PsA/SpA registry between March 2013 and March 2016 with non-missing data on axial involvement, defined as having a physician-reported presence of spinal involvement at enrollment, or an MRI or x-ray showing sacroiliitis. Descriptive analyses of patient demographics, clinical measures, patient-reported outcomes and treatment characteristics were reported at the time of enrollment for patients with vs without axial involvement. Statistical comparisons between subgroups were evaluated using P values from t-tests for continuous variables and chi-squared tests for categorical variables.

Results: As of March 2016, there were a total of 1530 patients with PsA in the Corrona PsA/SpA registry who had non-missing data on physician-reported axial involvement, including 192 patients (12.5%) with axial involvement and 1338 patients (87.5%) without axial involvement. Both subgroups were similar with regards to sex, race, body mass index, disease duration, overall presence of dactylitis and prevalence of most comorbidities (e.g., cardiovascular disease, any cancer, diabetes and serious infection). However, patients with axial involvement were younger (50.4 vs 54.4 years) and significantly more likely to have enthesitis (20.7% vs 19.2%), a history of depression (22.9% vs 12.6%) and biologic use (66.1% vs 54.3%) at enrollment compared to patients without axial involvement. Patients with axial involvement were also more likely to have moderate/severe psoriasis (body surface area > 3%) at enrollment compared with patients without axial involvement, and had worse disease as measured by nail psoriasis, enthesitis counts, achievement of minimal disease activity, AS disease activity and functional index scores, C-reactive protein levels and patient-reported outcomes (Table).

Conclusion: Data from the Corrona PsA/SpA registry showed that patients with PsA and axial involvement were more likely to have moderate/severe psoriasis with significantly higher disease activity at the time of registry enrollment compared to those without axial involvement. These findings demonstrate the overall impact of axial involvement on disease activity and highlight the importance of monitoring patients with PsA for signs of axial symptoms or spinal involvement on imaging.

References:

1.    Braun A, et al. Ann Rheum Dis. 2011;70(10):1782-7.


Disclosure: P. J. Mease, Celgene, Novartis, AbbVie, Amgen, BMS, Lilly, Pfizer and UCB, 2,Celgene, Corrona, Novartis, AbbVie, Amgen, BMS, Crescendo, Genentech, Janssen, Lilly, Merck, Pfizer and UCB, 5,AbbVie, Amgen, BMS, Crescendo, Celgene, Genentech, Janssen, Pfizer and UCB, 8; C. Karki, Corrona, LLC, 3; M. Liu, Corrona, LLC, 3; A. Kavanaugh, Amgen, AbbVie, Janssen, Pfizer and Novartis, 2; R. Pandurengan, Corrona, LLC, 3; C. T. Ritchlin, Amgen, Janssen Pharmaceutica Product, L.P., and UCB, 2,AbbVie, Amgen, Janssen Pharmaceutica Product, L.P., Regeneron, and UCB, 5; J. B. Palmer, Novartis Pharmaceuticals Corporation, 3; J. D. Greenberg, Corrona, LLC, 1,Corrona, LLC, 3,Eli Lilly, Genentech, Janssen, Novartis and Pfizer, 5.

To cite this abstract in AMA style:

Mease PJ, Karki C, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Palmer JB, Greenberg JD. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/influence-of-axial-involvement-on-clinical-characteristics-of-psoriatic-arthritis-descriptive-analysis-from-the-corrona-psoriatic-arthritisspondyloarthritis-psaspa-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-axial-involvement-on-clinical-characteristics-of-psoriatic-arthritis-descriptive-analysis-from-the-corrona-psoriatic-arthritisspondyloarthritis-psaspa-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology